Dexrazoxane: a second look. Prevention of anthracycline cardiotoxicity: useful for some patients.
In patients treated with anthracyclines, the addition of dexrazoxane moderately reduces the risk of symptomatic heart failure. But dexrazoxane increases the haematological toxicity induced by chemotherapy and might also reduce its antitumour efficacy.
D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D017277:Drug Approval; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control*; D005602:France; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D015201:Meta-Analysis as Topic; D011929:Razoxane / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*
D018943:Anthracyclines; D011929:Razoxane